HIS news
HIS / September 23, 2026
A completed phase 3 interventional trial conducted at Future University in Egypt assessed whether folic acid supplementation at 1 mg/day or 5 mg/day can reduce the frequency or severity of hot flashes induced by adjuvant endocrine therapy in premenopausal breast cancer patients. Full efficacy results have not yet been publicly reported.
Read news
HIS news
HIS / September 11, 2026
The IL Believe trial, sponsored by Ascendis Pharma, is a first-in-human Phase 1/2 dose-escalation and expansion study assessing the safety and tolerability of TransCon IL-2 β/γ—a novel investigational IL-2 prodrug—as monotherapy and in combination with pembrolizumab, TransCon TLR7/8 agonist, trastuzumab, T-DM1, or chemotherapy in adults with locally advanced or metastatic solid tumors. The trial is currently active but no longer enrolling.
Read news
HIS news
HIS / September 11, 2026
AstraZeneca is conducting a prospective, multicenter, single-arm Phase 4 trial evaluating the safety profile of trastuzumab deruxtecan (T-DXd) specifically in Indian patients with unresectable or metastatic HER2-positive breast cancer who have previously received an anti-HER2–based regimen. The trial is currently active but no longer enrolling.
Read news
HIS news
HIS / September 9, 2026
A randomized controlled trial found that mobile-delivered pain coping skills training (mPCST) is cost-effective and improves health-related quality of life in women with breast cancer residing in medically underserved areas.
Read news
HIS news
HIS / September 4, 2026
A tissue-free epigenomic circulating tumor DNA assay demonstrated strong prognostic value when applied at a 2-year post-adjuvant chemotherapy landmark in early-stage breast cancer, identifying individuals at elevated recurrence risk who may be candidates for early intervention. The findings, published in JCO Precision Oncology, support ctDNA-based risk stratification independent of tumor tissue availability.
Read news
HIS news
HIS / September 3, 2026
A phase 2 pilot trial at Johns Hopkins' Sidney Kimmel Comprehensive Cancer Center is enrolling patients with stage II/III triple-negative breast cancer to assess whether early PET imaging and biomarker changes after one cycle of paclitaxel/carboplatin/pembrolizumab can guide individualized neoadjuvant sequencing and rescue strategies.
Read news
HIS news
HIS / September 2, 2026
A completed Phase 1b/2 interventional trial evaluated the anti-HER2 bispecific antibody zanidatamab combined with docetaxel in HER2-positive breast cancer, and with tislelizumab plus chemotherapy (capecitabine/oxaliplatin) in HER2-positive gastric or gastroesophageal junction adenocarcinoma. The study assessed safety, tolerability, pharmacokinetics, and preliminary antitumor activity across both tumor types.
Read news
HIS news
HIS / August 28, 2026
The SWOG S0221 randomized phase III trial is evaluating two distinct doxorubicin/cyclophosphamide (AC) dosing schedules—continuous versus dose-dense biweekly—each followed by paclitaxel administered either every two weeks or weekly for 12 weeks, as post-operative adjuvant chemotherapy in node-positive or high-risk node-negative breast cancer. The trial is currently active but no longer enrolling.
Read news
HIS news
HIS / August 27, 2026
A systematic review of seven RCTs found that non-pharmacological interventions—particularly structured physical exercise—may improve overall quality of life and specific QoL domains in women with hormone receptor-positive breast cancer receiving adjuvant endocrine therapy, though high methodological heterogeneity limits definitive conclusions.
Read news
HIS news
HIS / August 26, 2026
The completed phase II TOUCH trial evaluated whether palbociclib combined with letrozole and dual HER2 blockade (trastuzumab plus pertuzumab) could replace paclitaxel-based chemotherapy in the neoadjuvant setting for postmenopausal women with HR+/HER2+ early breast cancer. The randomized, open-label, multicentre design aimed to determine whether a chemotherapy-sparing regimen could achieve comparable efficacy.
Read news
HIS news
HIS / August 24, 2026
A secondary analysis of the phase III APHINITY trial evaluated manual, digital, and AI-driven tumour-infiltrating lymphocyte scoring methods, assessing their comparative predictive utility in HER2-positive early breast cancer. Findings suggest AI-based TIL quantification may offer clinically meaningful prognostic and predictive information in this setting.
Read news
HIS news
HIS / August 21, 2026
The phase 2 BRE-10 INNOVATE trial is actively recruiting adults with IHC/FISH-confirmed HER2-positive early-stage breast cancer to evaluate whether MammaPrint®/BluePrint® genomic profiling can optimize neoadjuvant chemotherapy and HER2-targeted regimen selection. The interventional study is led by the University of Illinois at Chicago.
Read news
HIS news
HIS / August 19, 2026
A phase 2 interventional trial at Henan Cancer Hospital is actively recruiting to assess the efficacy and safety of the anti-PD-1 antibody serplulimab combined with nab-paclitaxel and epirubicin in the neoadjuvant setting for early-stage HR+/HER2− breast cancer. The study addresses a gap in immunotherapy integration within this historically chemotherapy-dependent subtype.
Read news
HIS news
HIS / August 17, 2026
A Phase 2 interventional trial at Memorial Sloan Kettering Cancer Center is actively enrolling adults aged 70 and older with early-stage breast cancer to assess the feasibility of dose-dense CMF (cyclophosphamide, methotrexate, fluorouracil) as an alternative to standard AC-based (doxorubicin/cyclophosphamide) chemotherapy regimens.
Read news
HIS news
HIS / August 13, 2026
A systematic review and meta-analysis of phase III trials examined whether menopausal status influences the adjuvant efficacy of CDK4/6 inhibitors in hormone receptor-positive early breast cancer. Findings suggest menopausal status may be a clinically relevant modifier of treatment benefit in this setting.
Read news
HIS news
HIS / August 6, 2026
A secondary analysis of the randomized STO-3 trial found that immune, endothelial, and fibroblast cell abundances within the tumor microenvironment significantly modulate long-term clinical benefit from tamoxifen in postmenopausal ER+/HER2− breast cancer. These findings implicate both immune and stromal compartments as determinants of endocrine therapy efficacy.
Read news
HIS news
HIS / July 31, 2026
The UNIRAD trial is a randomized, double-blind, multicenter Phase III study assessing whether adding everolimus to standard adjuvant endocrine therapy improves outcomes in women with ER+/HER2− primary breast cancer at high relapse risk due to extensive nodal involvement. The trial targets patients who have completed at least one year of adjuvant hormone therapy without disease recurrence.
Read news
HIS news
HIS / July 31, 2026
A UNICANCER-sponsored phase 3 interventional trial is now recruiting premenopausal women with HR+/HER2− early breast cancer to assess whether PAM50 genomic scoring (Prosigna®) can safely guide omission of adjuvant chemotherapy in favor of optimized endocrine therapy with ovarian function suppression. The primary endpoint is invasive disease-free survival compared against systematic chemo-endocrine therapy.
Read news
HIS news
HIS / July 30, 2026
A randomized controlled trial found that vaginal estrogen delivered superior relief of vaginal dryness and dyspareunia compared to non-hormonal vaginal moisturizer in breast cancer survivors on aromatase inhibitors, with evidence of minimal systemic estrogen absorption in most participants.
Read news
HIS news
HIS / July 24, 2026
A systematic review and meta-analysis published in PLOS ONE found that circulating microRNAs and lipidomic/metabolomic biomarkers demonstrate strong aggregate diagnostic performance for breast cancer detection, yet substantial heterogeneity and reliance on retrospective case-control designs preclude near-term clinical deployment.
Read news
HIS news
HIS / July 15, 2026
A meta-analysis of eight randomized and prospective trials found that novel HER2-directed therapies—including T-DXd, tucatinib, and margetuximab—significantly reduced mortality and disease progression risk compared with conventional regimens, with a more favorable cardiotoxicity and gastrointestinal adverse-effect profile.
Read news
HIS news
HIS / July 15, 2026
A completed Pfizer-sponsored Phase 2 randomized trial assessed the CDK inhibitor PF-07220060 combined with letrozole versus letrozole monotherapy as short-course neoadjuvant therapy in postmenopausal women with HR+/HER2− breast cancer. The 14-day interventional window incorporated mandatory Day 14 tumor biopsy to evaluate pharmacodynamic and safety endpoints.
Read news
HIS news
HIS / July 9, 2026
Updated subgroup analyses from the phase III JBCRG-M06/EMERALD trial compare eribulin mesylate against docetaxel or paclitaxel, each combined with trastuzumab and pertuzumab, as first-line therapy in HER2-positive locally advanced or metastatic breast cancer. The data provide additional granularity on efficacy and tolerability across clinically relevant subpopulations.
Read news
HIS news
HIS / June 24, 2026
The MolecularPCR Trial is a Phase II interventional study at MD Anderson Cancer Center investigating whether adjuvant therapy intensity can be safely reduced in patients with early HER2-positive breast cancer or TNBC who achieved pathologic complete response after neoadjuvant therapy and test negative for circulating molecular residual disease. The trial is currently recruiting.
Read news
HIS news
HIS / June 15, 2026
The CompassHER2 RD phase III randomized trial is investigating whether adding tucatinib to trastuzumab emtansine (T-DM1) improves relapse-free outcomes compared with T-DM1 alone in patients with HER2-positive breast cancer and residual disease following neoadjuvant therapy. The double-blinded trial is currently active but no longer enrolling.
Read news
HIS news
HIS / June 10, 2026
The lidERA Breast Cancer trial is a global Phase III randomized study comparing adjuvant giredestrant—an oral selective estrogen receptor covalent antagonist (SERCA)—against physician's choice of endocrine monotherapy in medium- and high-risk Stage I–III ER+/HER2− early breast cancer. The trial, sponsored by Hoffmann-La Roche, is currently active but no longer enrolling.
Read news
HIS news
HIS / June 1, 2026
A prospective interventional trial at Wake Forest University Health Sciences is actively enrolling to assess systemic high-dose methotrexate (8 g/m²) in breast cancer subtypes complicated by leptomeningeal metastasis, including cases with concurrent brain parenchymal involvement.
Read news
HIS news
HIS / May 15, 2026
A prospective randomized trial at Semmelweis University is investigating whether concomitant modulated electro-hyperthermia (mEHT) enhances pathologic response when added to standard neoadjuvant chemotherapy in stage II–III HER2-negative breast cancer. The trial is currently active but no longer enrolling participants.
Read news
HIS news
HIS / May 14, 2026
Memorial Sloan Kettering Cancer Center is enrolling participants in ARCHER, a randomized Phase II trial assessing whether consolidative locoregional surgery plus stereotactic body radiotherapy improves outcomes over standard systemic therapy alone in de novo oligometastatic HER2-positive breast cancer.
Read news
HIS news
HIS / May 14, 2026
An analysis from the Alliance A231701CD randomized controlled trial (NCT03766009) identifies key barriers preventing breast cancer patients from receiving adequate preparatory information before surgical consultations, along with actionable recommendations to address these gaps.
Read news
HIS news
HIS / May 13, 2026
A prospective, single-arm, multicenter phase 2 trial is now recruiting to assess the efficacy and safety of iparomlimab/tuvonralimab (QL1706) combined with paclitaxel and carboplatin in the neoadjuvant setting for HR+/HER2− breast cancer. The study is being conducted at RenJi Hospital.
Read news
HIS news
HIS / May 12, 2026
A double-blind, randomized phase III trial sponsored by the National Cancer Institute is investigating whether adding bevacizumab to standard adjuvant doxorubicin/cyclophosphamide followed by paclitaxel improves outcomes in lymph node-positive or high-risk lymph node-negative breast adenocarcinoma. The trial is currently active but no longer enrolling participants.
Read news
HIS news
HIS / May 12, 2026
A Hoffmann-La Roche–sponsored Phase 3 open-label extension study is actively collecting long-term safety and efficacy data on pertuzumab in patients with solid tumors who demonstrated no disease progression in a preceding pertuzumab parent trial. The study is currently active but no longer enrolling.
Read news
HIS news
HIS / May 6, 2026
The NeoTHERa phase II randomized trial is actively enrolling patients with HER2-amplified/positive early breast cancer to compare pathological complete response rates between docetaxel/trastuzumab/pertuzumab (THP) and docetaxel/carboplatin/trastuzumab/pertuzumab (TCHP) neoadjuvant regimens.
Read news
HIS news
HIS / May 3, 2026
A systematic review identifies antibody-drug conjugate–induced nausea and vomiting (ADCINV) as a prevalent, clinically meaningful adverse effect across multiple ADC agents, drawing parallels to chemotherapy-induced nausea and vomiting (CINV) and highlighting an unmet need for evidence-based antiemetic protocols.
Read news
HIS news
HIS / April 27, 2026
A Phase II interventional trial is investigating the combination of atezolizumab, pertuzumab, and high-dose trastuzumab in patients with HER2-positive metastatic breast cancer and central nervous system involvement. The trial is currently active but no longer enrolling participants.
Read news
HIS news
HIS / April 20, 2026
The HER2CLIMB-05 trial is a randomized, double-blind, phase 3 study assessing tucatinib versus placebo in combination with trastuzumab and pertuzumab as maintenance therapy for metastatic or locally advanced unresectable HER2-positive breast cancer. The trial, sponsored by Seagen (a Pfizer subsidiary), is currently active but no longer enrolling participants.
Read news
HIS news
HIS / April 20, 2026
AstraZeneca's Phase Ib/III CAPItello-292 trial is actively enrolling participants to assess whether adding the AKT inhibitor capivasertib to CDK4/6 inhibitor plus fulvestrant backbone therapy improves outcomes in locally advanced or metastatic HR+/HER2- breast cancer. The randomized, open-label design tests capivasertib in combination with palbociclib, ribociclib, or abemaciclib against CDK4/6 inhibitor–fulvestrant doublet therapy alone.
Read news
HIS news
HIS / April 19, 2026
An observational study at MD Anderson Cancer Center designed to evaluate quality of life in women who received breast cancer treatment while pregnant has been terminated. The trial's early closure leaves a gap in prospective data on this clinically complex population.
Read news
HIS news
HIS / April 19, 2026
A randomized, double-blind, placebo-controlled Phase III trial is assessing the efficacy and safety of TQB3616 capsules combined with standard endocrine therapy in approximately 1,946 women with HR-positive, HER2-negative breast cancer in the adjuvant setting. The trial, sponsored by Chia Tai Tianqing Pharmaceutical Group, is currently active but no longer enrolling.
Read news
